Inhibitory efficacy in platelet aggregation and pharmacokinetics of single oral administration of 300mg clopidogrel and 20mg prasugrel

Trial Profile

Inhibitory efficacy in platelet aggregation and pharmacokinetics of single oral administration of 300mg clopidogrel and 20mg prasugrel

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary)
  • Indications Acute coronary syndromes; Ischaemic heart disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Dec 2016 New trial record
    • 01 Nov 2016 Results published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top